一种CAR增强剂增加了CAR T细胞的活性和持久性
Taha Rakhshandehroo1, Shreya R Mantri1, Heydar Moravej1
1Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.
Nature biotechnology
|July 30, 2024
概括
一种新型的CAR增强剂 (CAR-E) 改善了多发性骨髓瘤的仿真抗原受体 (CAR) T细胞治疗. 这种CAR-E策略增强T细胞活动和记忆形成,可能导致更持久的缓解.
科学领域:
- 免疫学 免疫学 免疫学
- 细胞疗法细胞疗法
- 在瘤学瘤学.
背景情况:
- 化学抗原受体 (CAR) T细胞疗法显示出有希望的结果,但往往缺乏持久的缓解.
- 与CAR T细胞疗法相关的有限疗效和毒性需要新的策略.
研究的目的:
- 开发和评估CAR增强剂 (CAR-E) 策略,以提高CAR T细胞治疗的疗效和耐用性.
- 研究BCMA-IL-2 CAR-E在多发性骨髓瘤治疗中的潜力.
主要方法:
- 通过将CAR T细胞抗原 (BCMA) 与免疫调节分子 (低亲和IL-2) 融合,开发一种CAR增强剂 (CAR-E).
- 在多发性骨髓瘤模型中,BCMA CAR-E T 细胞的体外和体内评估.
- 机制研究以阐明CAR-E的作用机制.
主要成果:
- BCMA CAR-E选择性地增强了CAR T细胞的增殖,激活和抗瘤活性.
- 通过CAR-E治疗,增加了具有增强重新扩张能力的记忆CAR-T细胞的产生.
- 这种方法表明减少了IL-2相关的毒性,并使较低的细胞剂量治疗成为可能.
结论:
- CAR-E方法代表了一种有希望的策略,以提高多发性髓瘤的CAR T细胞疗法的疗效和耐久性.
- 这种新的方法提供了一种改善CAR T细胞治疗结果的潜在途径,同时减轻毒性和减少细胞剂量要求.
相关概念视频
Tumor Immunotherapy
498
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
498
T Cell Activation and Clonal Selection
693
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
693
Cells of the Adaptive Immune Response
972
The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
972
T Cell Types and Functions
967
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
967
B Cell Activation and Differentiation
1.7K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
1.7K
Cell-mediated Immune Responses
68.0K
Overview
68.0K


